{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:46:51Z","timestamp":1784544411908,"version":"3.55.0"},"reference-count":15,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Bispecific antibodies (BsAbs) are a promising therapy for relapsed\/refractory multiple myeloma (RRMM), but their efficacy in patients with end-stage renal disease (ESRD) on peritoneal dialysis (PD) remains unclear. Given the prevalence of renal impairment in MM, understanding BsAbs\u2019 use in this population is critical.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Report<\/jats:title>\n                    <jats:p>We present a 72-year-old woman with ESRD on PD diagnosed with RRMM after developing a pathologic humeral fracture. Bone marrow biopsy confirmed lambda light chain multiple myeloma with extensive skeletal involvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management &amp; Outcome<\/jats:title>\n                    <jats:p>The patient was treated with upfront radiation, and then received daratumumab, cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD), followed by carfilzomib, lenalidomide, and dexamethasone (KRd) upon progression. Due to limited response, teclistamab was initiated, achieving a significant but transient response, prompting a switch to talquetamab. Following relapse, she was transitioned to elotuzumab, pomalidomide, and dexamethasone, then selinexor as a bridge to chimeric antigen receptor T-cell (CAR-T) therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case demonstrates that BsAbs may be effective in RRMM patients on PD, though responses were transient. Further research is needed to explore BsAbs\u2019 pharmacokinetics, optimal dosing, and long-term outcomes in dialysis-dependent MM patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251341235","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T03:56:37Z","timestamp":1747108597000},"page":"1179-1182","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Using bispecific antibodies in a patient with peritoneal dialysis for relapsed multiple myeloma"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0887-4493","authenticated-orcid":false,"given":"Heng","family":"Jiang","sequence":"first","affiliation":[{"name":"Westchester Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yagya","family":"Ahlawat","sequence":"additional","affiliation":[{"name":"Westchester Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Westchester Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-23-0176"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00806-w"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.3.301"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180660"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241242022"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27063"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_3_2_11_2","volume-title":"TECVAYLI\u00ae [Prescribing Information]","unstructured":"TECVAYLI\u00ae [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. Accessed December 19th, 2024. https:\/\/www.tecvaylihcp.com\/discover-science\/"},{"key":"e_1_3_2_12_2","volume-title":"TALVEY\u00ae [Prescribing Information]","unstructured":"TALVEY\u00ae [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. Accessed February 17th, 2025. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TALVEY-pi.pdf"},{"key":"e_1_3_2_13_2","unstructured":"U.S. Food and Drug Administration. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. Accessed December 19th 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI107023"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2018.00138"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251341235","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251341235","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251341235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:31:12Z","timestamp":1777689072000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251341235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/10781552251341235"],"URL":"https:\/\/doi.org\/10.1177\/10781552251341235","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]}}}